Business Context and Reporting Period
This Form 8-K Current Report was filed by Processa Pharmaceuticals, Inc. on October 13, 2020, covering events occurring on October 6, 2020. The Company is a biopharmaceutical entity focused on infectious diseases, oncology, and rare diseases, with its principal executive offices in Hanover, Maryland.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The report focuses exclusively on executive compensation and employment terms.
Material Changes
The primary material change reported is the appointment of R. Michael Floyd as Chief Operating Officer (COO), effective October 1, 2020. This appointment was formalized via an employment agreement entered into on October 6, 2020.
Management Commentary and Compensation Details
- Executive Appointment: R. Michael Floyd, age 64, was appointed COO. He brings over 15 years of experience in early-stage biopharma, including roles at Neurologic, Arpida Ltd., Gentium, Bio-AIM, and Elion Oncology.
- Compensation Package:
- Annual base salary: $87,500.
- Equity grant: 50,000 Restricted Stock Units (RSUs) of common stock.
- Vesting schedule: 25% annually over 4 years.
- Termination Provisions: In the event of termination without Cause or for Good Reason, the Company must provide 52 weeks' written notice. RSUs fully vest upon a Change in Control or such termination. A severance payment may be provided at the Company's discretion.
- Benefits: Mr. Floyd is entitled to participate in all standard employee benefits.
Investor Verification Checklist
- Verify the full text of the Employment Agreement filed as Exhibit 10.1 for specific definitions of "Cause," "Good Reason," and "Change in Control."
- Review the press release filed as Exhibit 99.1 for additional strategic context regarding the COO appointment.
- Confirm the current trading status of PCSA on The Nasdaq Stock Market LLC.
- Note that this filing contains no financial performance data; refer to the most recent 10-K or 10-Q for financial metrics.